. Author manuscript; available in PMC: 2014 Jul 1.

Published in final edited form as: Free Radic Biol Med. 2013 Feb 14;60:10.1016/j.freeradbiomed.2013.02.003. doi: 10.1016/j.freeradbiomed.2013.02.003

Table 2.

Hematological chemotherapeutic sensitivity in the WEHI7.2 cells and the WEHI7.2 variants.

Cell Variant	Cyclophosphamide EC₅₀ (mM)^a	Doxorubicin EC₅₀ (nM)^a	Doxorubicin EC₉₀ (nM)^a	Vincristine EC₅₀ (nM)^a	Vincristine EC₉₀ (nM)^a	Dexamethasone (% apoptosis)^b
WEHI7.2^#	1.82 ± 0.03	8.60 ± 0.58	23.74 ± 0.65	2.37 ± 0.17	4.26 ± 0.34	23.79 ± 1.30
200R^#	5.71 ± 0.18^*	11.40 ± 1.11	28.66 ± 0.72^*	9.01 ± 3.90	48.43 ± 3.53^*	10.16 ± 0.28^*
Hb12	6.34 ± 0.39^*	23.36 ± 0.84^*		63.43 ± 2.80^*		2.51 ± 0.30^*

Values represent the mean ± SEM (n ≥ 3).

Values are the mean percent apoptosis after a 24h treatment with 1 μM dexamethasone corrected for % apoptosis in vehicle-treated cells (n = 3).

These data have been previously published (6).

denotes significantly different from WEHI7.2 values (p ≤ 0.05).